Hongzi Chen

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Urinary Tract Infection

Placebo Controlled

Candida Albicans

Top Venues

Antimicrobial agents and chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy (2024)
Greg Moeck, Leanne B Gasink, Rodrigo Elisandro Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M E Wagenlehner, Tim Henkel, Paul C McGovern
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial agents and chemotherapy 68 (7) (2024)